New Cannabinoid Therapy Targeting Fibromyalgia Is Being Tested

cannabis-Manuel-flickr.jpg

Clinical trials are being done by Israel’s Intec Pharma on AP-CBD/THC, a pharmaceutical that contains two cannabinoids - cannabidiol (CBD), and tetrahydrocannabinol (THC) - found in Cannabis sativa.

AP-CBD/THC is intended to relieve chronic pain disorders, including fibromyalgia. It uses the Accordion Pill (AP) platform, a method of delivery that extends the absorption phase of CBD and THC for enhanced therapeutic effect. The AP system is meant to resolve problems with current cannabinoid use, such as delayed onset, short duration of effect, variable exposure, and dosage, and adverse issues related to peak levels.

The Accordion Pill platform delivers oral drugs on a biodegradable multi-layer structure that is folded into a capsule-sized accordion shape. The accordion unfolds in the stomach, delivering the drug in a controlled manner for up to 12 hours. The AP mechanism eventually degrades in the intestine.

The Phase 1 trial will compare the body response and safety of two AP-CBD/THC formulations against an oral spray containing CBD and THC called Buccal Sativex.

“The progression of AP-CBD/THC into the clinic is a significant achievement for Intec and marks a major step forward in developing a potential new therapy for pain management,” said Intec Pharma’s CEO, Zeev Weiss in a press release. “It is also our first demonstration of the Accordion Pill platform for cannabinoid therapies.”

Cannabis-derived medication is a burgeoning aspect of the specialty pharmaceutical market, and is rapidly gaining attention in the medical community. Future studies will evaluate the AP delivery system for other conditions where safe, prolonged cannabinoid therapy may provide relief.

Sources: Fibromyalgia News Today; Intec Pharma
Photo credit: M a n u e l


disclaimer

The information provided on MyFibro.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of MyFibro.com nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.

 

Fibromyalgia is a prevalent condition that affects many people in the United States. Approximately 3.7 million Americans have Fibromyalgia. That is 1 in every 73 people.

More Quick Facts...

Fibromyalgia Videos

fibromyo